NCT07208591View on ClinicalTrials.gov

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

406

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2026

Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
DRUG

STSA-1002 injection

basal treatment + STASA-1002 intravenous infusion

DRUG

STSA-1002 Injection Placebo

basal treatment + STSA-1002 Injection Placebo

Trial Locations (3)

100029

China-Japan Friendship Hospital, Beijing

411100

Xiangtan Central Hospital, Xiangtan

450003

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors
lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY